: small molecule : Foley Hoag Newsroom

Home > small molecule >

Where is the Capital Going? Dana Gordon on Biotechnology Investing

Posted on May 12, 2009 by Foley Hoag LLP

Tags: BIO 2009, Dana Gordon, biotech, drug discovery, funding, small molecule

Foley Hoag Newsroom
Published by Foley Hoag LLP

Attorney advertising.
Prior results do not guarantee
a similar outcome.

Foley Hoag LLP

Seaport World Trade Center West
155 Seaport Boulevard

Boston, MA 02210-2600

tel:

617 832 1000

fax:

617 832 7000

Foley Hoag LLP

1875 K Street., N.W., Suite 800

Washington, D.C. 20006-1238

tel:

202 223 1200

fax:

202 785 6687

Emerging Enterprise Center at Foley Hoag LLP

Bay Colony Corporate Center, North Entrance
1000 Winter Street - Suite 4000

Waltham, MA 02451-1238

tel:

781 895 5900

fax:

781 895 5999

Foley Hoag Newsroom, published by Foley Hoag LLP, a leading national law firm in the areas of dispute resolution, intellectual property, and corporate transactions for emerging, middle-market, and large-cap companies, offers news, videos, TV and press releases, press kit, fact sheets, related to the firm and its 225 lawyers, attorneys, counsel, from our offices in Boston, MA and Washington, DC, as well as from the firm’s Emerging Enterprise Center in Waltham, Massachusetts.

Foley Hoag Newsroom : Lawyers & Attorneys at Foley Hoag Law Firm : Press Releases & Videos

Published By Foley Hoag LLP

Hot Topics - Industry Insight - Legal Trends

Where is the Capital Going? Dana Gordon on Biotechnology Investing

Jeffrey Quillen on Biotech Survival Strategies

The False Claims Act and The Life Sciences Industry: More to Come

Patent Portfolios in a Down Economy: Smart and Strategic Investments

What Bilski Means to Biotech: Barbara Fiacco on the Significance of This Patent Litigation